An interventional study of Proximal lower limb ultrasound in Deep Vein Thrombosis and Pulmonary Embolism, sponsored by King Abdullah International Medical Research Center. Recruiting at 1 site in Saudi Arabia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by King Abdullah International Medical Research Center · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The DETECT randomized controlled trial addresses the question of whether surveillance ultrasound in critically ill patients by facilitating DVT detection reduces the incidence of PE and lowers all-cause 90-day mortality. The primary outcome is 90-day all-cause mortality.
This is an open-label multicenter multinational randomized-controlled trial. All patients admitted to ICU will be screened within the first 48 hours of ICU admission for eligibility. Subjects who meet all criteria for enrollment will be randomized via a password-protected, secure website using a variable-size block concealed computer-generated randomization procedure. Patients will be allocated to twice weekly bilateral lower limb ultrasound or standard care (control) in a 1:1 ratio.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
This study's planned enrollment of 1,800 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Browse Venous Thrombosis studies →King Abdullah International Medical Research Center is the lead sponsor of 46 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be receiving twice weekly proximal lower limb ultrasound
Diagnostic Test: Proximal lower limb ultrasound
Proximal lower limb ultrasound will be performed as per the treating team discretion
Twice weekly proximal lower limb ultrasound
90-day mortality
Mortality 90 days post randomization
Time frame: 90 days
Proximal DVT
Lower limb proximal leg DVT, defined as partially or completely incompressible venous segment.
Time frame: From randomization date to day 28 or ICU discharge whichever comes first
Pulmonary Embolism
Pulmonary embolism defined as definite PE (characteristic intraluminal filling defect on CT chest, high probability VQ scan or detected at autopsy); probable PE (moderate-high pretest, no test or a non-diagnostic test); possible PE (low pre-test probability, non-diagnostic test) or No PE (negative or normal test)
Time frame: From randomization date and throughout hospital stay up to day 28
Clinically important bleeding
Fatal bleeding, symptomatic bleeding in critical organ or bleeding causing fall in hemoglobin, requiring transfusion or interventional radiology
Time frame: From randomization date and throughout hospital stay up to day 90
Mechanical ventilation-free days
Total number of days alive and free of mechanical ventilation within 28 days after randomization
Time frame: 28 days
Vasopressor-free days
Total number of days alive and free of vasopressor use within 28 days after randomization
Time frame: 28 days
Days alive and out of hospital by day 90
Days alive and out of the hospital at day 90 calculated by using the days from alive at hospital discharge to day 90
Time frame: 90 days
Plan to share: Yes — The data supporting this study's findings will be available from the corresponding author upon reasonable request as per the regulations of King Abdullah International Medical Research Center (KAIMRC).
Time frame: After the publication of the main manuscript (Primary outcome analysis)
Access criteria: Proposal that describes planned analyses must be submitted along with a data sharing agreement
Started Mar 2023 (actual). Primary completion is estimated for Mar 2026, 36 months after the start.
Of 99 non-industry interventional studies with no phase under Venous Thrombosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 36 months is close to that.
Counting every sponsor, half of 117 studies reached it within 34 months; a quarter within 13 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King Abdullah International Medical Research Center